GlassScriptPhysician profile
Christian T Ruff
NPI 1760420061
$211,462.55
in general payments reported to CMS, 2019-2025
17 companies · $32K in 2025
The $32K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $29K · 2021: $2,366 · 2022: $39K · 2023: $16K · 2024: $12K · 2025: $32K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Travel and Lodging: $4,797 · Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $54,225.50 |
| Travel and Lodging | $4,797.27 |
| Food and Beverage | $1,023.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim International Gmbh | $40,486.98 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $38,104.28 | 2019-2020 | |
| Janssen Research & Development, LLC | $32,304.95 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $20,350.86 | 2025 | |
| Janssen Global Services, LLC | $17,056.56 | 2020-2022 | |
| Daiichi Sankyo Company LTD | $15,045.00 | 2022-2023 | Savaysa |
| Astrazeneca Pharmaceuticals LP | $10,800.00 | 2023-2024 | Lokelma |
| E.R. Squibb & Sons, L.L.C. | $9,100.00 | 2020-2022 | |
| Regeneron Pharmaceuticals, INC. | $7,697.64 | 2024-2025 | |
| Pfizer INC. | $5,671.68 | 2019 | |
| Merck Sharp & Dohme LLC | $3,815.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $2,800.00 | 2020 | |
| Amag Pharmaceuticals, INC. | $2,400.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $2,366.00 | 2021 | |
| Roche Diagnostics Corporation | $1,644.44 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beckman Coulter, INC. | $1,575.00 | 2024 | |
| Janssen Scientific Affairs, LLC | $244.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Ruff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.